Paul Tak is the founder of Candel Therapeutics. Candel Therapeutics has raised $147M in total funding. Latest round: IPO. Based in United States.
Paul Peter Tak is the CEO of Candel Therapeutics, a biopharmaceutical company focused on developing oncolytic viral immunotherapies for cancer. He has guided the company through a $79.1 million IPO and previously through Series B and C funding rounds. Currently, Tak is working to expand Candel's management team and acquire additional capital to further the company's immunotherapy efforts.
Full founder directory · Investor directory · Company funding database · Fundraising library